Sign in to view content

Twelve Month Safety and Efficacy Outcomes from a Phase 2 Study of APL-2 in Patients with Geographic Atrophy

David S. Boyer, MD

Video
Published 2017

Related

Phase 3 Randomized, Double-Masked Studies of Brolucizumab Versus Aflibercept in nAMD: Expanded Primary and Secondary Outcomes From HAWK/HARRIER
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2018
Quantitative Contrast Sensitivity Longitudinal Changes Correlate Better Than Visual Acuity With Geographic Atrophy Progression
John B. Miller, MD
Annual Meeting Talks
2024
Therapies for Diabetic Macular Edema: What’s in the Pipeline?
Peter K. Kaiser, MD FASRS
Updates from the Field
2018

Category: AMD-Neovascular

See more